HUE026654T2 - Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére - Google Patents
Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére Download PDFInfo
- Publication number
- HUE026654T2 HUE026654T2 HUE05792486A HUE05792486A HUE026654T2 HU E026654 T2 HUE026654 T2 HU E026654T2 HU E05792486 A HUE05792486 A HU E05792486A HU E05792486 A HUE05792486 A HU E05792486A HU E026654 T2 HUE026654 T2 HU E026654T2
- Authority
- HU
- Hungary
- Prior art keywords
- szilárd
- rix
- matrix
- compound
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Claims (9)
- ÙJ gyôgpÿe^s késxtîpêpys ÄslsnSä 4"(4-(3-(4~k?6Tvi'Pifliiöm5.et:0-feftil)--iu«klö>3~üiäür~fß»oxl)'' ïpîMispsssli Is^lésérfi Szabadakat igéoyp ontok1. Készítmény, amely legalább 4-|4.{3~(44#rks4ïiiStPnnéd}'-iioii|-ps^^ ksripssavHped! -apidok alapvetően sppffônAsn és gyégysxsréssstiSeg elfogadható mátrixot tartalmazd szilárd diszpetziói tartalmaz.
- 2. Âz 1. tgàsypiîxi síserlsű ké^faôty» alot a mátrix tartalmaz akStrsikezók alkotta psoptatböl vtlaszioh: 0ó|p3sírásp4ilsg slfeipdhatp fgÉImsft: polivkoi-pínüiidoö, v¾í^piπ'ôlkbîï/viïl:ö-~âee!:à; kopoilmor, pölmlkiÄrglkok poMmiiémgikcd, hiàpxsAiâ-'ÇSËuldÂ, kîte4%mpllp^l4tej ^dp^îgîliîlPsetil-cgHalé^ Mài®^p^îli«i«tü^ïulô^· Wtó«*9É1"ie&«J% ï)àîria«Î-katb(«iisîgilp^îplà^ eilmsipMx, pcdimemkrilätok, pídivinllPl&ohok poiimpilmcst% vi»ü--alköho{/yIai!4p^ip|p8*^:i.p!^a:oiMli gltptsídek, kmstiogami, karmgés, kitöÄ, Ä. imlldsxtnm
- 3. Az l. Igénypont szeriftti készítmény, ató § mátrix tartalmas a következők alkotta csoportból választott cukrot ds/vagy «akör^alköholt; Is^agy dklodoxtriat: szacharóz, laktős, ir&któs, oaaltós, raffrnő& $)ZsMi lakdk maaskj ípakit, «rktit, á^:^J^8ÍŐ%: Irmait, kodsn, msltodextrim ßmiklodesdn«, Mdroxipropib pmlklödfixirfe és spdiyfeaíÜ-dPp-ciklodsxkfák 4,. M'$. igésypôapSKSïârtikèsÂiteényj aixd alköíp esojprtbdl választott gyŐgysxerésZfitlleg Mdroxlproplbeellalőz, hiÉxpípdpil-patífe cellulóz és ppiifidlémglllml. 5. & 2. igénypont szerinti kásxilméríyy ahol a mátrix tarmimaz pöilkipiipktplldpa. 6. A 2. igénypont szerinti készítmény, ahol & mánix tartsM&ä kidroxipropgmellpi&t
- 7. Készítmény, amely legalább 4* {4-f3<4*kl<^-3ddff«ometü'feajl}-mei<k|^fiat|!|N*ö5d}«phi<üft-2«> karböss&ymr«di--smkiöi, szolvétjaít, htdrátj&ft, gyégyszerészetUeg elfogadható sait vagy fikék kombinációit és gyógyszarésaetílfig fii fogadhat 6 mátrixot tartalmazó szilárd diszpesziót tartalmaz, ahol mátrix tartalmaz a következők alkotta csoportból választott iyógy$mrt:saesileg elfogadható polimert: polivimi-pirrohdon. virul-pitTolidon/vitsíl-acstái ; kopölím*m, pol laikiiért-gMköl, peliKrilén-gítköl, hidt οχ lalkü-celhílóz, h Idtoxiptopil -csikóik, hldroxialklhmedlmallukk, hidrPxipreíiS>«r«^Ní«^«tó2. karboxImedkxîilriièSjpâtrmot-karboximedk esilalSa,: etioadkbk, poiimeî&krilâtok, psrtMtiitPikoiiol, j^lMail-acetâî, vsrsl KsíksöíissIíVíxtil^c.éSÉtfkoyí«! mxöí', poHpikokáált glseoridfik, x&taákpnm kanagén, khozám kitin, poiklsatrm, dmirist, fesïdésytêJs Éshérjék, S. KészSknény, stooly legalább 4..{4d3'{4^i^-3“bifl«otmetjl-fenil}'ts«i||dip|^flüi3iÎèKôâ8}-piri<^»>t.“ karhöpsay-tootikaispldpt, moiväi|ibt> hídrátjak, gyógysserészetileg elfogadható sóit Vágy ezek kombinációit és gyógysafirészstllfig élfdgpdható isitrixoi tartalmazó szilái diszperztől tartalmaz, sliól piátrix taitsiksaz a kövfidípzők alköim esopodhdl vsilasaíea etskrot és/vagy- s.pskoi'-slkokoh es/vagy ükiddaxtdst; má&imréz^ Jákt&z, feiktsá,mákóz, raüaóz, mmaiéz, morttáK,malin, mallpésxirto,. |ri 9. A 7. igénypont szedni készítmény, ahol a mátrix mémî «gy, s következők alkotta mapori bói választott gyógyszerészéitől; éliogadható polimert; polMml-pimtHdon, hsdroxiproptl OeUulóz, Indroxípmpik mstil-eeíMőz és poíietüén-giikol. Ili 7. igé«yporsl::à^ôCMs^!œéftÿvstel:àÂt»iirta]maxpoUvk«ipin®|dçpt Ily A 7. Igénypont szbfei készítmény »hol & mátrix tartalmaz hiánjxi'propll-célkdóxí.
- 12. Az előző Igéttypentok bármelyike szerinti fcéariönésvy, mi mába alkalmazásra szánt gyógyszerészeti készítmény.
- 13. Az előzd igénypontok bármelyike .szerimi készítmény,, mai tabletta formájában lévő gyógyszerészeti készítmény.
- 14. Az előző igénypontok bármelyike szerinti készítmény, ami kapszula formájában lévő gyégys.íetészt'ííkészitméfíy.
- 15. Az mézé igénypontók bánselyik« s;æ£&ÉbÉ®Éi|y, and por vágy grannléintn forifopban lévő jfyőgyszerészeír készítmény. 16 Eiísrő. %>{4 p^44riór«3-tnü»otmetörfemi ‘ meitfevI^flaÂ^xîl-piridîô^ÎÈÂ^â^ÈBlÉ’^ÉÉà: szilárd diszperziójának előállítására alapvétőét) amorf formában, amely tartalmaz egy, a következők alkotta csoportból választott módszert: foziós/őntiedék . technológia, meleg őmledék (kot melt) eximáálás, oldószer feepártas, fagyasztva szárítás, porlasztva szárítás, porok vagy granblátömak rétegzése, együttes lecsapás, sznperkrítlkys folyadék technológia és elektrosztatikus azál.képzés, 17. A» 145. igénypontok bármelyike szerinti gj^|ysz®Rfes^:tóxiteény tópétpri^átotiv rendellenességek kezelésében történő alkalmazásra emlősöknél, ideértve az embert, vagy egyetlen azsíMgt vagy más terápiákkal kombinálva,
- 18.. Ág 1* í 5. igénypontok bármelyike szerinri gyógyszerészei készítmény tik kezelésébe! príáttő lá^ma^m'iióiNóteélriái^ye az embert, vagy egyeben szerként vagy más terápiákkal komlpáívst. 19. áiilS. igénylőtök bármelyike szermi gyógyszerészei készítmény rák kezelésében törtéai IMmazásrs karip bstegyfo kombinálva egy eietpgikssg tenáptával.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60475204P | 2004-08-27 | 2004-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE026654T2 true HUE026654T2 (hu) | 2016-07-28 |
Family
ID=35517032
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE05792486A HUE026654T2 (hu) | 2004-08-27 | 2005-08-29 | Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére |
HUS1700047C HUS1700047I1 (hu) | 2004-08-27 | 2017-11-21 | Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS1700047C HUS1700047I1 (hu) | 2004-08-27 | 2017-11-21 | Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére |
Country Status (41)
Country | Link |
---|---|
US (2) | US20060058358A1 (hu) |
EP (2) | EP1793824B1 (hu) |
JP (1) | JP5017115B2 (hu) |
KR (1) | KR101336737B1 (hu) |
CN (2) | CN102885813A (hu) |
AR (1) | AR050616A1 (hu) |
AU (1) | AU2005279996A1 (hu) |
BR (1) | BRPI0514715B1 (hu) |
CA (1) | CA2578438C (hu) |
CL (1) | CL2010001484A1 (hu) |
CR (1) | CR8980A (hu) |
CY (1) | CY2017038I2 (hu) |
DK (1) | DK1793824T3 (hu) |
EA (1) | EA010832B1 (hu) |
EC (1) | ECSP077299A (hu) |
ES (1) | ES2561618T3 (hu) |
GT (1) | GT200500230A (hu) |
HN (1) | HN2005000484A (hu) |
HR (1) | HRP20160156T1 (hu) |
HU (2) | HUE026654T2 (hu) |
IL (1) | IL181590A (hu) |
LT (1) | LTC1793824I2 (hu) |
LU (1) | LUC00047I2 (hu) |
MA (1) | MA28911B1 (hu) |
ME (2) | ME00152B (hu) |
MX (1) | MX2007002397A (hu) |
MY (1) | MY191349A (hu) |
NI (1) | NI200700064A (hu) |
NO (2) | NO343937B1 (hu) |
NZ (1) | NZ553557A (hu) |
PE (2) | PE20100432A1 (hu) |
PL (1) | PL1793824T3 (hu) |
PT (1) | PT1793824E (hu) |
RS (1) | RS54580B1 (hu) |
SI (1) | SI1793824T1 (hu) |
TN (1) | TNSN07076A1 (hu) |
TW (1) | TWI369987B (hu) |
UA (1) | UA92472C2 (hu) |
UY (1) | UY29086A1 (hu) |
WO (1) | WO2006026500A1 (hu) |
ZA (1) | ZA200702392B (hu) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2725000A (en) * | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
BRPI0515946A (pt) * | 2004-09-29 | 2008-08-12 | Bayer Healthcare Ag | sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo |
CN104688697A (zh) * | 2005-03-07 | 2015-06-10 | 拜尔健康护理有限责任公司 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20090074917A2 (en) * | 2006-07-26 | 2009-03-19 | Remington Direct Lp | Low-calorie, no laxation bulking system |
US20080026038A1 (en) * | 2006-07-26 | 2008-01-31 | Remington Direct Lp | No laxation, low flatulence bulking system |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
CA2667720A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
EP2155166A2 (en) * | 2007-05-11 | 2010-02-24 | F. Hoffmann-Roche AG | Pharmaceutical compositions for poorly soluble drugs |
US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
US9101631B2 (en) | 2008-12-12 | 2015-08-11 | Georgetown University | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer |
JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
CN103002880B (zh) * | 2010-06-09 | 2015-01-28 | Abbvie公司 | 含有激酶抑制剂的固态分散体 |
WO2012009388A1 (en) | 2010-07-12 | 2012-01-19 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
CA2805874A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
SG189038A1 (en) | 2010-10-01 | 2013-05-31 | Bayer Ip Gmbh | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
JP6068352B2 (ja) | 2010-10-29 | 2017-01-25 | アッヴィ・インコーポレイテッド | アポトーシス誘発剤を含む固体分散体 |
CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
UY35006A (es) | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
US9211290B2 (en) * | 2012-12-31 | 2015-12-15 | Noven Therapeutics, Llc | Solid dispersions of amorphous paroxetine mesylate |
WO2015049698A2 (en) * | 2013-10-04 | 2015-04-09 | Hetero Research Foundation | Process for regorafenib |
CN104721142B (zh) * | 2013-12-18 | 2020-04-28 | 山东新时代药业有限公司 | 一种利伐沙班固体分散体及其制备方法 |
US9790185B2 (en) | 2014-07-09 | 2017-10-17 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
EP4137132A1 (en) | 2016-09-30 | 2023-02-22 | Salix Pharmaceuticals, Inc. | Solid dispersion forms of rifaximin |
CN111166724A (zh) * | 2018-11-09 | 2020-05-19 | 北京化工大学 | 一种瑞戈非尼纳米分散体、片剂及其制备方法 |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
CN112587485A (zh) * | 2021-01-08 | 2021-04-02 | 湖南南新制药股份有限公司 | 一种药物固体分散体及其制备方法 |
CN112842998A (zh) * | 2021-01-19 | 2021-05-28 | 深圳市简一生物科技有限公司 | 一种瑞戈非尼分散剂及其制备方法 |
FR3123358B1 (fr) | 2021-05-25 | 2024-05-10 | Vecormat Bfc | Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle. |
WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
CN114767633B (zh) * | 2022-04-07 | 2023-03-31 | 郑州大学第一附属医院 | 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
US4220302A (en) | 1978-07-21 | 1980-09-02 | Hampton Diane M | Nursing bottle holder |
ATE159426T1 (de) * | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
DE69831013T2 (de) * | 1997-12-22 | 2006-04-20 | Bayer Pharmaceuticals Corp., West Haven | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
NZ505843A (en) * | 1997-12-22 | 2003-06-30 | Bayer Ag | Diphenyl ureas compounds for treating cancer and raf kinase related diseases |
ID26328A (id) * | 1997-12-22 | 2000-12-14 | Bayer Ag | Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
MEP36908A (en) * | 1999-01-13 | 2011-02-10 | Bayer Corp | omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
AU2725000A (en) * | 1999-01-13 | 2000-08-01 | Bayer Corporation | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
JP3789066B2 (ja) | 1999-12-08 | 2006-06-21 | 三菱電機株式会社 | 液晶表示装置 |
HUP0300429A2 (hu) * | 2000-04-19 | 2003-07-28 | Fujisawa Pharmaceutical Co., Ltd. | Javított felszívódási képességű szilárd diszperzió és eljárás az előállítására |
US8725620B2 (en) | 2000-07-10 | 2014-05-13 | Nobuyoshi Morimoto | System and method for negotiating improved terms for products and services being purchased through the internet |
EP1308156A4 (en) * | 2000-08-11 | 2009-07-15 | Eisai R&D Man Co Ltd | AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY |
EP1350792A1 (en) | 2000-12-11 | 2003-10-08 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE324871T1 (de) * | 2001-02-13 | 2006-06-15 | Astrazeneca Ab | Neue formulierung mit modifizierter freisetzung |
SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
EP1578346A4 (en) * | 2001-12-04 | 2007-11-28 | Onyx Pharma Inc | INHIBITORS OF THE RAF-MEK-ERK PATHWAY TO TREAT CANCER |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
RU2004123621A (ru) * | 2002-02-01 | 2005-04-10 | Пфайзер Продактс Инк. (Us) | Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств |
MXPA04007832A (es) * | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
CA2430180C (en) | 2003-05-21 | 2010-03-16 | Royal Group Technologies Limited | Cascade shade |
PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
ATE395905T1 (de) * | 2004-08-27 | 2008-06-15 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
-
2005
- 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
- 2005-08-26 TW TW094129395A patent/TWI369987B/zh active
- 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
- 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
- 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
- 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
- 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
- 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
- 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
- 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
- 2005-08-29 HU HUE05792486A patent/HUE026654T2/hu unknown
- 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
- 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
- 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
- 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
- 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko active IP Right Review Request
- 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
- 2005-08-29 CA CA2578438A patent/CA2578438C/en active Active
- 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
- 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
- 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
- 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
- 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
- 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
- 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es active Active
- 2005-08-29 RS RS20160039A patent/RS54580B1/en unknown
- 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
- 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en active Application Filing
- 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
- 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja active Active
- 2005-08-29 NZ NZ553557A patent/NZ553557A/en unknown
- 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
-
2007
- 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
- 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
- 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
- 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
- 2007-03-07 CR CR8980A patent/CR8980A/es unknown
- 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
- 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
- 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
-
2010
- 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
-
2016
- 2016-02-12 HR HRP20160156TT patent/HRP20160156T1/hr unknown
- 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
-
2017
- 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
- 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
- 2017-11-09 CY CY2017038C patent/CY2017038I2/el unknown
- 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
-
2019
- 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1793824T3 (en) | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluoro-phenoxy) -pyridine-2-carboxylic acid to the treatment of hyperproliferative DISORDERS | |
EP1796642B1 (en) | Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer | |
WO2012172461A1 (en) | Pharmaceutical compositions of febuxostat | |
CN108495620B (zh) | 包含苯基氨基嘧啶衍生物的药物组合物 | |
US20200323838A1 (en) | Lenalidomide immediate release formulations | |
WO2013001441A1 (en) | Dry formulations of febuxostat | |
JP2024508970A (ja) | (4s)-24-クロロ-4-エチル-73-フルオロ-35-メトキシ-32,5-ジオキソ-14-(トリフルオロメチル)-32h-6-アザ-3(4,1)-ピリジナ-1(1)-[1,2,3]トリアゾラ-2(1,2),7(1)-ジベンゼナヘプタファン-74-カルボキサミドを含んでいる医薬剤形 | |
AU2011244932B9 (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
US20230075876A1 (en) | Pharmaceutical composition containing regorafenib and a stabilizing agent | |
JP2021113183A (ja) | 非晶質トルバプタンを含む固形製剤及びその製造方法 |